Contributions of mitogen‐activated protein kinase and nuclear factor kappa B to N‐(4‐hydroxyphenyl)retinamide–induced apoptosis in prostate cancer cells
Authors:
- 29 October 2002
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 35 (3) , 127-137
Abstract
The synthetic retinoid N‐(4‐hydroxyphenyl)retinamide (4‐HPR) has been shown to induce apoptosis in various types of tumors, including prostate cancer. We sought to examine the key mechanisms affecting the resistance to 4‐HPR–induced apoptosis in three human prostate cancer cell lines, PC‐3, DU145, and LNCaP. Concentrations of more than 40 μM 4‐HPR produced apoptosis to almost the same extent in all cell lines; however, only the LNCaP line remained highly sensitive to concentrations less than 10 μM. These differing sensitivities at low concentrations correlated well with the level of constitutive activation of nuclear factor kappa B (NFκB) in the individual cell lines. We found that NFκB activation inhibited c‐jun NH2‐terminal kinase and caspase 3 activation induced by 4‐HPR and that NFκB inhibition by the I kappa B alpha phosphorylation inhibitor compound Bay 117082 resulted in increasing sensitization of both PC‐3 and DU145 lines to apoptosis induced by 4‐HPR at low concentrations. Furthermore, we found that inhibition of extracellular signal–regulated kinase (ERK) enhanced the suppression of NFκB by 4‐HPR and also resulted in sensitization to apoptosis in the DU145 cell line, in which ERK is activated constitutively. It thus appears that mitogen‐activated protein kinase associated with the activity of NFκB plays an important role in the degree of resistance to 4‐HPR‐induced apoptosis in human prostate cancer cells.Keywords
This publication has 29 references indexed in Scilit:
- MEK Inhibition Enhances Paclitaxel-induced Tumor ApoptosisJournal of Biological Chemistry, 2000
- VEGF Prevents Apoptosis of Human Microvascular Endothelial Cells via Opposing Effects on MAPK/ERK and SAPK/JNK SignalingExperimental Cell Research, 1999
- Phase II Chemoprevention Trial of Oral Fenretinide in Patients at Risk for Adenocarcinoma of the ProstateAmerican Journal of Clinical Oncology, 1997
- NF-κB: Ten Years AfterCell, 1996
- Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expressionInternational Journal of Cancer, 1996
- Opposing Effects of ERK and JNK-p38 MAP Kinases on ApoptosisScience, 1995
- Retinoids in Cancer ChemopreventionAnnals of the New York Academy of Sciences, 1995
- Control of IκB-α Proteolysis by Site-Specific, Signal-Induced PhosphorylationScience, 1995
- Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: Implications for chemopreventionJournal of Cellular Biochemistry, 1995
- Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.Journal of Clinical Oncology, 1993